Efficacy of Adjuvant First-Generation TKIs versus Chemotherapy in Patients with Completely Resected EGFR-Mutant Non-Small Cell Lung Cancer: A Meta-Analysis

References

• Pass H, Giroux D, Kennedy C, Ruffini E, Cangir AK, Rice D, International Association for the Study of Lung Cancer Staging and Prognostic Factors Committee, et al. The IASLC lung cancer staging project: proposals for revision of the TNM stage groupings in the forthcoming (Eighth) edition of the TNM classification for lung. J Thorac Oncol. 2016;11(12):2082–2088. doi:10.1016/j.jtho.2016.09.123.
   PubMed Web of Science ®Google Scholar
• Vansteenkiste J, Wauters E, Reymen B, Ackermann CJ, Peters S, De Ruysscher D. Current status of immune checkpoint inhibition in early-stage NSCLC. Ann Oncol. 2019; Aug 130(8):1244–1253. doi:10.1093/annonc/mdz175.
   PubMed Web of Science ®Google Scholar
• Burdett S, Pignon JP, Tierney J, Tribodet H, Stewart L, Le Pechoux C, Non‐Small Cell Lung Cancer Collaborative Group, et al. Adjuvant chemotherapy for resected early-stage non-small cell lung cancer. Cochrane Database Syst Rev. 2015;2015(3):CD011430. Mar 2;doi:10.1002/14651858.CD011430.
   PubMedGoogle Scholar
• Bradbury P, Sivajohanathan D, Chan A, Kulkarni S, Ung Y, Ellis PM. Postoperative adjuvant systemic therapy in completely resected non-small-cell lung cancer: a systematic review. Clin Lung Cancer. 2017; May18(3):259–273.e8. doi:10.1016/j.cllc.2016.07.002.
   PubMed Web of Science ®Google Scholar
• Pignon JP, Tribodet H, Scagliotti GV, Douillard JY, Shepherd FA, Stephens RJ, LACE Collaborative Group, et al. Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group. J Clin Oncol. 2008;26(21):3552–3559. Jul 20 doi:10.1200/JCO.2007.13.9030.
   PubMed Web of Science ®Google Scholar
• Pepe C, Hasan B, Winton TL, Seymour L, Graham B, Livingston RB, National Cancer Institute of Canada and Intergroup Study JBR.10, et al. Adjuvant vinorelbine and cisplatin in elderly patients: National Cancer Institute of Canada and Intergroup Study JBR.10. J Clin Oncol. 2007;25(12):1553–1561. Apr 20 doi:10.1200/JCO.2006.09.5570.
   PubMed Web of Science ®Google Scholar
• Petrelli F, Barni S. Non-cancer-related mortality after cisplatin-based adjuvant chemotherapy for non-small cell lung cancer: a study-level meta-analysis of 16 randomized trials. Med Oncol. 2013;30(3):641. doi:10.1007/s12032-013-0641-5.
   PubMed Web of Science ®Google Scholar
• Wakelee HA, Dahlberg SE, Keller SM, Tester WJ, Gandara DR, Graziano SL, ECOG-ACRIN, et al. Adjuvant chemotherapy with or without bevacizumab in patients with resected non-small-cell lung cancer (E1505): an open-label, multicentre, randomised, phase 3 trial. Lancet Oncol. 2017;18(12):1610–1623. Dec doi:10.1016/S1470-2045(17)30691-5.
   PubMed Web of Science ®Google Scholar
• Esteban E, Majem M, Martinez Aguillo M, Martinez Banaclocha N, Dómine M, Gómez Aldaravi L, et al. Prevalence of EGFR mutations in newly diagnosed locally advanced or metastatic non-small cell lung cancer Spanish patients and its association with histological subtypes and clinical features: The Spanish REASON study. Cancer Epidemiol. 2015; Jun39(3):291–297. doi:10.1016/j.canep.2015.02.003.
   PubMed Web of Science ®Google Scholar
• Shi Y, Au JS, Thongprasert S, Srinivasan S, Tsai CM, Khoa MT, et al. A prospective, molecular epidemiology study of EGFR mutations in Asian patients with advanced non-small-cell lung cancer of adenocarcinoma histology (PIONEER). J Thorac Oncol. 2014; Feb9(2):154–162. doi:10.1097/JTO.0000000000000033.
   PubMed Web of Science ®Google Scholar
• Han B, Tjulandin S, Hagiwara K, Normanno N, Wulandari L, Laktionov K, et al. EGFR mutation prevalence in Asia-Pacific and Russian patients with advanced NSCLC of adenocarcinoma and non-adenocarcinoma histology: The IGNITE study. Lung Cancer. 2017; Nov113:37–44. doi:10.1016/j.lungcan.2017.08.021.
   PubMed Web of Science ®Google Scholar
• Zhou F, Zhou C. Lung cancer in never smokers-the East Asian experience. Transl Lung Cancer Res. 2018; Aug7(4):450–463. doi:10.21037/tlcr.2018.05.14.
   PubMed Web of Science ®Google Scholar
• Zhong WZ, Wang Q, Mao WM, Xu ST, Wu L, Shen Y, Liu YY, ADJUVANT investigators, et al. Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage II-IIIA (N1-N2) EGFR-mutant NSCLC (ADJUVANT/CTONG1104): a randomised, open-label, phase 3 study. Lancet Oncol. 2018;19(1):139–148. Jan doi:10.1016/S1470-2045(17)30729-5.
   PubMed Web of Science ®Google Scholar
• He J, Su C, Liang W, Xu S, Wu L, Fu X, et al. Icotinib versus chemotherapy as adjuvant treatment for stage II-IIIA EGFR-mutant non-small-cell lung cancer (EVIDENCE): a randomised, open-label, phase 3 trial. Lancet Respir Med. 2021; Sep9(9):1021–1029. doi:10.1016/S2213-2600(21)00134-X.
   PubMed Web of Science ®Google Scholar
• Yue D, Xu S, Wang Q, Li X, Shen Y, Zhao H, et al. Erlotinib versus vinorelbine plus cisplatin as adjuvant therapy in Chinese patients with stage IIIA EGFR mutation-positive non-small-cell lung cancer (EVAN): a randomised, openlabel, phase 2 trial. Lancet Respir Med. 2018;6(11):863–873. doi:10.1016/S2213-2600(18)30277-7.
   PubMed Web of Science ®Google Scholar
• Kelly K, Altorki NK, Eberhardt WEE, O'Brien MER, Spigel DR, Crinò L, et al. Adjuvant erlotinib versus placebo in patients with stage IB-IIIA nonsmall-cell lung cancer (RADIANT): a randomized, double-blind, phase III trial. J Clin Oncol. 2015;33(34):4007–4014. doi:10.1200/JCO.2015.61.8918.
   PubMed Web of Science ®Google Scholar
• Tada H, Mitsudomi T, Misumi T, Sugio K, Tsuboi M, Okamoto I, West Japan Oncology Group, et al. Randomized phase III study of gefitinib versus cisplatin plus vinorelbine for patients with resected stage II-IIIA non-small-cell lung cancer with EGFR mutation (IMPACT). J Clin Oncol. 2022;40(3):231–241. Jan 20 doi:10.1200/JCO.21.01729.
   PubMed Web of Science ®Google Scholar
• Chen RL, Sun LL, Cao Y, Chen HR, Zhou JX, Gu CY, et al. Adjuvant EGFR-TKIs for patients with resected EGFR-mutant non-small cell lung cancer: a meta-analysis of 1,283 patients. Front Oncol. 2021; Apr 1211:629394. doi:10.3389/fonc.2021.629394.
   PubMed Web of Science ®Google Scholar
• Li M, Hou X, Lin S, Zheng L, Liang J, Chen J, et al. Efficacy of adjuvant EGFR inhibitors and impact of clinical factors in resected EGFR-mutated non-small-cell lung cancer: a meta-analysis. Future Oncol. 2022; Mar18(9):1159–1169. doi:10.2217/fon-2021-0934.
   PubMed Web of Science ®Google Scholar
• Zhao P, Zhen H, Zhao H, Zhao L, Cao B. Efficacy and safety of adjuvant EGFR-TKIs for resected non-small cell lung cancer: a systematic review and meta-analysis based on randomized control trials. BMC Cancer. 2022; Mar 2622(1):328. doi:10.1186/s12885-022-09444-0.
   PubMed Web of Science ®Google Scholar
• Holleman MS, Al MJ, Zaim R, Groen HJM, Uyl-de Groot CA. Cost-effectiveness analysis of the first-line EGFR-TKIs in patients with non-small cell lung cancer harbouring EGFR mutations. Eur J Health Econ. 2020; Feb21(1):153–164. doi:10.1007/s10198-019-01117-3.
   PubMed Web of Science ®Google Scholar
• Hirsh V, Singh J. Optimal sequencing strategies in the treatment of EGFR mutation-positive non-small cell lung cancer: Clinical benefits and cost-effectiveness. Am J Health Syst Pharm. 2020; Sep 477(18):1466–1476. doi:10.1093/ajhp/zxaa197.
   PubMed Web of Science ®Google Scholar
• Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003; Sep 6327(7414):557–560. doi:10.1136/bmj.327.7414.557.
   PubMed Web of Science ®Google Scholar
• DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986; Sep7(3):177–188. doi:10.1016/0197-2456(86)90046-2.
   PubMedGoogle Scholar
• Sterne JA, Egger M. Funnel plots for detecting bias in meta-analysis: guidelines on choice of axis. J Clin Epidemiol. 2001; Oct54(10):1046–1055. doi:10.1016/s0895-4356(01)00377-8.
   PubMed Web of Science ®Google Scholar
• Zhong WZ, Wang Q, Mao WM, Xu ST, Wu L, Wei YC, et al. Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage II-IIIA (N1-N2) EGFR-mutant NSCLC: final overall survival analysis of CTONG1104 phase III trial. J Clin Oncol. 2021; Mar 139(7):713–722. doi:10.1200/JCO.20.01820.
   PubMed Web of Science ®Google Scholar
• Kenmotsu H, Yamamoto N, Yamanaka T, Yoshiya K, Takahashi T, Ueno T, et al. Randomized phase III study of pemetrexed plus cisplatin versus vinorelbine plus cisplatin for completely resected stage II to IIIA nonsquamous non-small-cell lung cancer. J Clin Oncol. 2020; Jul 138(19):2187–2196. doi:10.1200/JCO.19.02674.
   PubMed Web of Science ®Google Scholar
• Wu YL, Tsuboi M, He J, John T, Grohe C, Majem M, et al. Osimertinib in resected EGFR-mutated non-small-cell lung cancer. N Engl J Med. 2020;383(18):1711–1723. doi:10.1056/NEJMoa2027071.
   PubMed Web of Science ®Google Scholar
• Alden RS, Mandrekar SJ, Oxnard GR. Designing a definitive trial for adjuvant targeted therapy in genotype defined lung cancer: the ALCHEMIST trials. Chin Clin Oncol. 2015; Sep4(3):37. doi:10.3978/j.issn.2304-3865.2015.09.03.
   PubMed Web of Science ®Google Scholar